Development of a multivariate prediction model of intensive care unit transfer or death: A French prospective cohort study of hospitalized COVID-19 patients.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2020
Historique:
received: 14 05 2020
accepted: 01 10 2020
entrez: 19 10 2020
pubmed: 20 10 2020
medline: 3 11 2020
Statut: epublish

Résumé

Prognostic factors of coronavirus disease 2019 (COVID-19) patients among European population are lacking. Our objective was to identify early prognostic factors upon admission to optimize the management of COVID-19 patients hospitalized in a medical ward. This French single-center prospective cohort study evaluated 152 patients with positive severe acute respiratory syndrome coronavirus 2 real-time reverse transcriptase-polymerase chain reaction assay, hospitalized in the Internal Medicine and Clinical Immunology Department, at Pitié-Salpêtrière's Hospital, in Paris, France, a tertiary care university hospital. Predictive factors of intensive care unit (ICU) transfer or death at day 14 (D14), of being discharge alive and severe status at D14 (remaining with ventilation, or death) were evaluated in multivariable logistic regression models; models' performances, including discrimination and calibration, were assessed (C-index, calibration curve, R2, Brier score). A validation was performed on an external sample of 132 patients hospitalized in a French hospital close to Paris, in Aulnay-sous-Bois, Île-de-France. The probability of ICU transfer or death was 32% (47/147) (95% CI 25-40). Older age (OR 2.61, 95% CI 0.96-7.10), poorer respiratory presentation (OR 4.04 per 1-point increment on World Health Organization (WHO) clinical scale, 95% CI 1.76-9.25), higher CRP-level (OR 1.63 per 100mg/L increment, 95% CI 0.98-2.71) and lower lymphocytes count (OR 0.36 per 1000/mm3 increment, 95% CI 0.13-0.99) were associated with an increased risk of ICU requirement or death. A 9-point ordinal scale scoring system defined low (score 0-2), moderate (score 3-5), and high (score 6-8) risk patients, with predicted respectively 2%, 25% and 81% risk of ICU transfer or death at D14. Therefore, in this prospective cohort study of laboratory-confirmed COVID-19 patients hospitalized in a medical ward in France, a simplified scoring system at admission predicted the outcome at D14.

Identifiants

pubmed: 33075088
doi: 10.1371/journal.pone.0240711
pii: PONE-D-20-14374
pmc: PMC7571674
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0240711

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist. This does not alter our adherence to PLOS ONE policies on sharing data and materials.

Références

Int J Infect Dis. 2020 May;94:154-155
pubmed: 32179137
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
Stat Med. 2019 Mar 30;38(7):1276-1296
pubmed: 30357870
Clin Infect Dis. 2020 Jul 28;71(15):748-755
pubmed: 32239127
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
JAMA. 2020 Apr 28;323(16):1545-1546
pubmed: 32167538
J Infect. 2020 Jun;80(6):639-645
pubmed: 32240670
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Stat Med. 2019 Mar 30;38(7):1262-1275
pubmed: 30347470
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Ann Med. 2020 Nov;52(7):367-375
pubmed: 32723107
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Chest. 2020 Jul;158(1):106-116
pubmed: 32275978
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930

Auteurs

Yves Allenbach (Y)

Department of Internal Medicine and Clinical Immunology, Centre National de Références Maladies Autoimmunes et Systémiques Rares Maladies Autoinflammatoires Rares et des Myopathies Inflammatoires, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne University, Paris, France.

David Saadoun (D)

Department of Internal Medicine and Clinical Immunology, Centre National de Références Maladies Autoimmunes et Systémiques Rares Maladies Autoinflammatoires Rares et des Myopathies Inflammatoires, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne University, Paris, France.

Georgina Maalouf (G)

Department of Internal Medicine and Clinical Immunology, Centre National de Références Maladies Autoimmunes et Systémiques Rares Maladies Autoinflammatoires Rares et des Myopathies Inflammatoires, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne University, Paris, France.

Matheus Vieira (M)

Department of Internal Medicine and Clinical Immunology, Centre National de Références Maladies Autoimmunes et Systémiques Rares Maladies Autoinflammatoires Rares et des Myopathies Inflammatoires, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne University, Paris, France.

Alexandra Hellio (A)

Department of Internal Medicine and Clinical Immunology, Centre National de Références Maladies Autoimmunes et Systémiques Rares Maladies Autoinflammatoires Rares et des Myopathies Inflammatoires, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne University, Paris, France.

Jacques Boddaert (J)

Department of Geriatrics, Sorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.

Hélène Gros (H)

Robert-Ballanger Hospital, Aulnay-sous-Bois, France.

Joe Elie Salem (JE)

Department of Pharmacology and Clinical Investigation Center, Sorbonne Université, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, CIC Pitié-Salpêtrière (CIC-1901), Paris, France.

Matthieu Resche Rigon (M)

Department of Biostatistics and Medical Information, AP-HP Saint-Louis University Hospital; ECSTRRA Team, CRESS UMR 1153, INSERM, University of Paris, Paris, France.

Cherifa Menyssa (C)

Department of Biostatistics and Medical Information, AP-HP Saint-Louis University Hospital; ECSTRRA Team, CRESS UMR 1153, INSERM, University of Paris, Paris, France.

Lucie Biard (L)

Department of Biostatistics and Medical Information, AP-HP Saint-Louis University Hospital; ECSTRRA Team, CRESS UMR 1153, INSERM, University of Paris, Paris, France.

Olivier Benveniste (O)

Department of Internal Medicine and Clinical Immunology, Centre National de Références Maladies Autoimmunes et Systémiques Rares Maladies Autoinflammatoires Rares et des Myopathies Inflammatoires, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne University, Paris, France.

Patrice Cacoub (P)

Department of Internal Medicine and Clinical Immunology, Centre National de Références Maladies Autoimmunes et Systémiques Rares Maladies Autoinflammatoires Rares et des Myopathies Inflammatoires, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne University, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH